Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models

Abstract Unresectable hepatocellular carcinoma (uHCC) is one of the most lethal and prevalent cancers worldwide, and current systemic therapeutic options for uHCC are limited. Lenvatinib, a multiple receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs) an...

Full description

Saved in:
Bibliographic Details
Main Authors: Masahiro Matsuki, Taisuke Hoshi, Yuji Yamamoto, Megumi Ikemori‐Kawada, Yukinori Minoshima, Yasuhiro Funahashi, Junji Matsui
Format: Article
Language:English
Published: Wiley 2018-06-01
Series:Cancer Medicine
Subjects:
angiogenesis
fibroblast growth factor
hepatocellular carcinoma
Lenvatinib
vascular endothelial growth factor
Online Access:https://doi.org/10.1002/cam4.1517
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items